|Target disease||Bordetella pertussis|
|Legal status||℞ Prescription only|
|ATC code||J07 J07|
| (what is this?)
Pertussis vaccine is a component of the DPT vaccine.
Older versions of pertussis vaccine involved inactivated cells. Newer versions are acellular, and are less likely to provoke a febrile state.
In 2005, two new vaccine products were licensed for use in adolescents and adults that combine the tetanus and diphtheria toxoids with acellular pertussis (Tdap) vaccine. These vaccines are the first acellular pertussis-containing vaccines that make it possible to vaccinate adolescents and adults against pertussis.
Estimates of acellular pertussis vaccine efficacy range from 84% to 85% in preventing typical whooping cough. Acellular vaccine containing at least 3 protective antigens was shown to be of higher or similar efficacy to the previously-used whole cell pertussis vaccine, however the efficacy of the acellular vaccine declines faster. Despite widespread vaccination, pertussis has persisted in vaccinated populations and is one of the most prevalent vaccine-preventable diseases. The recent resurgence in pertussis infections is put down to a combination of waning immunity and new mutations in the pathogen that existing vaccines are unable to effectively control.
Local reactions, such as fever, redness and swelling at the injection site, and soreness and tenderness where the shot was given, are not uncommon in children and adults. These minor local and systemic adverse reactions are much less common with acellular DTaP vaccine; however, a determination of more rare adverse effects can only be made when additional data are available following extended use of DTaP.
Administration in Pregnancy
It was announced that the Whooping cough vaccine would be made available to all pregnant woman in the UK from 1 September 2012.
- "MedlinePlus Medical Encyclopedia: Pertussis". Retrieved 2010-07-02.
- Patel SS, Wagstaff AJ (Aug 1996). "Acellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection". Drugs 52 (2): 254–275. PMID 8841742.
- http://www.vaccineinformation.org/pertuss/qandavax.asp[dead link]
- Zhang L, Prietsch SOM, Axelsson I, Halperin SA (2012). "Acellular vaccines for preventing whooping cough in children". Cochrane Database of Systematic Reviews (3): CD001478. doi:10.1002/14651858.CD001478.pub5. PMID 22419280.
- Allen, A. (2013). "The Pertussis Paradox". Science 341 (6145): 454–455. doi:10.1126/science.341.6145.454.
- Mooi et. al. (Feb. 2013). "Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin.". Epidemiology and Infection (Oxford University Press): 1–10. doi:10.1017/S0950268813000071.
- van der Ark et. al. (Sep. 2012). "Resurgence of pertussis calls for re-evaluation of pertussis animal models.". Expert Reviews 11 (9). doi:10.1586/erv.12.83.